
FDA Approves Aducanumab — A Controversial Drug For Alzheimer's
Short Wave
00:00
The Approval of Aducanumab: A New Hope or Controversial Gamble in Alzheimer's Treatment
This chapter explores the FDA's approval of the Alzheimer’s drug aducanumab, detailing its controversy and implications for patients and healthcare providers. It examines the scientific foundations of amyloid drugs, the history of Alzheimer’s treatment failures, and the mixed sentiments of optimism and skepticism among developers.
Play episode from 01:43
Transcript


